Quelling of Excitotoxicity in Acute Stroke With Ketamine

• Status: Not yet recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Doylestown Health; Lower Merion Neurology Research Foundation
• Treatments: Ketamine; Midazolam

Criteria

Inclusion Criteria:

1. All patients who are 18 years or older, presenting or admitted to the study site with acute ischemic stroke, up to 24 hours since their last known well time

2. An MRI evidence of acute ischemic infarct on the diffusion-weighted imaging with ADC correlate

3. Pre-stroke modified Rankin scale of 0-2

4. Patient should be willing to participate in the study by providing a written consent himself/herself or through a proxy.

Exclusion Criteria:

1. Eligibility to receive IV Alteplase or intra-arterial thrombectomy/embolectomy

2. Longer than 24 hours since last known well time

3. Pre-stroke modified Rankin scale of 3 or above.

4. Pregnant or lactating females

5. Pre-existing psychiatric illness

6. Intracranial hemorrhage of any type at presentation

7. Seizure at onset of symptoms

8. Sustained uncontrolled hypertension defined as Systolic Blood pressure greater than 185 mmHg or Diastolic Blood Pressure greater than 110 mmHg, despite administration of antihypertensive medications

9. Known hypersensitivity or adverse reaction to prior administration of Ketamine

10. Inability/refusal to provide consent by the patient or through a proxy